2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
1
Active Trials
200 recruiting
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Myeloid Therapeutics, Inc. is a company with 2 orphan drug designations across 3 rare diseases. Active clinical trials in 1 indication.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| T-cell non-Hodgkin lymphoma | Autologous modified RNA transfected myeloid cells that express a fusion protein composed of humanized scFv that recognizes human CD5, a CD8 alpha transmembrane domain, and Fc gamma and PI3K intracellular signaling domains (CD5-ATAK-Fcy-PI3K Myeloid Cells) | Des.TrialAppr. |
| hepatocellular carcinoma | anti-GPC3-CD89 mRNA encapsulated within lipid nanoparticles | Des.TrialAppr. |
| ovarian cancer | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
15
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
15
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio